Cargando…
Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis
Glioblastoma (GBM) is a refractory disease with a poor prognosis and various methods, including maximum resection and immunotherapy, have been tested to improve outcomes. In this retrospective study we analyzed the prognostic factors of 277 newly diagnosed GBM patients over 11 years of consecutive c...
Autores principales: | Ishikawa, Eiichi, Sugii, Narushi, Matsuda, Masahide, Kohzuki, Hidehiro, Tsurubuchi, Takao, Akutsu, Hiroyoshi, Takano, Shingo, Mizumoto, Masashi, Sakurai, Hideyuki, Matsumura, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287820/ https://www.ncbi.nlm.nih.gov/pubmed/34281518 http://dx.doi.org/10.1186/s12883-021-02318-1 |
Ejemplares similares
-
High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis
por: Matsuda, Masahide, et al.
Publicado: (2023) -
RT-02 POTENTIAL OF PROTON BEAM THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
por: Matsuda, Masahide, et al.
Publicado: (2019) -
RT-4 Treatment outcome of proton beam therapy for glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2021) -
Levetiracetam Versus Levetiracetam Plus Sodium Channel Blockers for Postoperative Epileptic Seizure Prevention in Brain Tumor Patients
por: Watanabe, Noriyuki, et al.
Publicado: (2022) -
P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients
por: Yamada, Erika, et al.
Publicado: (2023)